4-Methoxy-5,6-dimethyl-pyrimidin | 25589-19-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-Methoxy-5,6-dimethyl-pyrimidin
• 英文别名: 4-methoxy-5,6-dimethyl-pyrimidine；4-Methoxy-5,6-dimethylpyrimidine
• CAS: 25589-19-9
• 化学式: C₇H₁₀N₂O
• 分子量: 138.169
• InChiKey: KUWABBHSSROSGS-UHFFFAOYSA-N

物化性质

• 沸点：
  118 °C(Press: 40 Torr)
• 密度：
  1.043±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  35
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• [EN] BICYCLIC HETEROARYL DERIVATIVES AS KINASE INHIBITORS<br/>[FR] DÉRIVÉS HÉTÉROARYLES BICYCLIQUES EN TANT QU'INHIBITEURS DE KINASE
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2013078254A1

  公开（公告）日：2013-05-30

  The present invention provides compounds, including resolved enantiomers, resolved diastereomers, solvates and pharmaceutically acceptable salts thereof, comprising the Formula 1: wherein Het, X, R1 and R2 are as defined herein.

  本发明提供了化合物，包括已分离的对映体、已分离的异构体、溶剂合物和其药学上可接受的盐，其化学式如下：其中Het、X、R1和R2的定义如本文所述。
• [EN] RIPK1 INHIBITORS AND METHODS OF USE<br/>[FR] INHIBITEURS DE RIPK1 ET PROCÉDÉS D'UTILISATION
  申请人：MERCK SHARP & DOHME

  公开号：WO2021252307A1

  公开（公告）日：2021-12-16

  Described herein are compounds of Formula (I) or a pharmaceutically acceptable salt thereof. The compounds of Formula (I) act as RIPK1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for RIPK1-related diseases.

  本文描述的是化合物的结构式（I）或其药用可接受的盐。式（I）化合物作为RIPK1抑制剂，可用于预防、治疗或作为RIPK1相关疾病的治疗剂。
• Pyrrolo-Pyridine, Pyrrolo-Pyrimidine and Related Heterocyclic Compounds
  申请人：Yuan Jun

  公开号：US20080267887A1

  公开（公告）日：2008-10-30

  Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds analogues of the formula: wherein R, R 2 , R 5 , E, Z 1 , Z 3 , Z 4 , and Ar are defined herein. Such compounds are ligands of C5a receptors. Preferred pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds of the invention bind to C5a receptors with high affinity and exhibit neutral antagonist or inverse agonist activity at C5a receptors. The present invention also relates to pharmaceutical compositions comprising such compounds, and to the use of such compounds in treating a variety of inflammatory, cardiovascular, and immune system disorders. In addition, the present invention provides labeled pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds, which are useful as probes for the localization of C5a receptors.

  吡咯吡啶、吡咯嘧啶和相关杂环化合物的类似物的公式如下： 其中R，R2，R5，E，Z1，Z3，Z4和Ar在此定义。这些化合物是C5a受体的配体。本发明所述的优选吡咯吡啶、吡咯嘧啶和相关杂环化合物以高亲和力结合到C5a受体，并在C5a受体上表现出中性拮抗剂或反向激动剂活性。本发明还涉及包含这些化合物的药物组合物，并且涉及使用这些化合物治疗各种炎症、心血管和免疫系统疾病。此外，本发明提供了标记的吡咯吡啶、吡咯嘧啶和相关杂环化合物，这些化合物可用作C5a受体的定位探针。
• TRISUBSTITUTED AMINE COMPOUND
  申请人：NAKAMURA Yoshinori

  公开号：US20110092506A1

  公开（公告）日：2011-04-21

  The present invention relates to a compound of the general formula (1): wherein, Y is a methylene group, and the like; A is an optionally substituted heterocyclic group, and the like; B is an optionally substituted phenyl group, and the like; R 1 is an optionally substituted alkyl group, and the like; and R 2 is an optionally substituted amino group, and the like; or a pharmaceutically acceptable derivative thereof, which has an inhibitory activity against cholesteryl ester transfer protein (CETP), thereby being useful for prophylaxis and/or treatment of arteriosclerotic diseases, hyperlipemia or dyslipidemia, and the like.

  本发明涉及一种通式（1）的化合物：其中，Y是亚甲基基团等；A是可选取的取代杂环基团等；B是可选取的取代苯基团等；R1是可选取的取代烷基团等；R2是可选取的取代氨基团等；或其药学上可接受的衍生物。该化合物具有对胆固醇酯转移蛋白（CETP）的抑制活性，因此可用于预防和/或治疗动脉硬化性疾病、高脂血症或血脂异常等。
• PYRROLO-PYRIDINE, PYRROLO-PYRIMIDINE AND RELATED HETEROCYCLIC COMPOUNDS
  申请人：Yuan Jun

  公开号：US20110118273A1

  公开（公告）日：2011-05-19

  Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds analogues of the formula: wherein R, R 2 , R 5 , E, Z 1 , Z 3 , Z 4 , and Ar are defined herein. Such compounds are ligands of C5a receptors. Preferred pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds of the invention bind to C5a receptors with high affinity and exhibit neutral antagonist or inverse agonist activity at C5a receptors. The present invention also relates to pharmaceutical compositions comprising such compounds, and to the use of such compounds in treating a variety of inflammatory, cardiovascular, and immune system disorders. In addition, the present invention provides labeled pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds, which are useful as probes for the localization of C5a receptors.

  吡咯并吡啶、吡咯并嘧啶和相关杂环化合物的类似物的公式为：其中R、R2、R5、E、Z1、Z3、Z4和Ar的定义如下。这些化合物是C5a受体的配体。本发明所述的优选吡咯并吡啶、吡咯并嘧啶和相关杂环化合物以高亲和力结合到C5a受体，并在C5a受体上表现出中性拮抗剂或反向激动剂活性。本发明还涉及包含这些化合物的制药组合物，以及使用这些化合物治疗各种炎症、心血管和免疫系统疾病的用途。此外，本发明提供了标记的吡咯并吡啶、吡咯并嘧啶和相关杂环化合物，这些化合物可用作C5a受体的定位探针。